PhD candidate in political science in DCP-USP. Master in Public Administration and Government at the São Paulo School of Business Administration, Fundação Getulio Vargas (EAESP/FGV), with a FAPESP grant. Graduated in Public Administration at the same school, she was a FAPESP Scholarship holder for Scientific Initiation (October/2018 - December/2019) and a Research Internship Scholarship Abroad (BEPE - July/2019-October/2019), with which she was a visiting researcher, from July to October/2019, at the Universitat Autònoma de Barcelona (UAB). She was a FAPESP Masters scholarship holder, and was a visiting researcher at the Universitat Pompeu Fabra (BEPE-March-July/2021).She worked as a researcher on the project "Judicialization of Supplementary Health: an empirical analysis using big data and artificial intelligence" (P.I.: Daniel Wei Liang Wang). Currently, she is a consultant at the Institute for Health Policy Studies (IEPS). Her research focuses on comparative health policies and systems, with an emphasis on federative and/or decentralized countries' responses to health crises. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
One of the critical problems of contemporary health systems is how to provide access to life-saving direct-acting antivirals (DAAs) to treat the hepatitis C virus (HCV). Given the promising results of such therapies, the World Health Organization (WHO) launched a strategy to eliminate hepatitis C as a public health emergency, but only a small group of countries have taken serious steps to…
This proposal aims at developing typology for comparing national approaches toward the regulation of generic drugs, and to map out a research strategy for applying this typology in the Latin American. Generic drug substitution may constitute a core instrument of countries' National Pharmaceutical Policies, a way to reduce the price of drugs while expanding access to health care. Yet despi…
The COVID-19 pandemic is a great challenge for global public health, and it is testing health systems, evidencing, however, that state capacity is not enough to explain the countries performance in fighting disease. It is also necessary to analyze the "political capacity" to respond to epidemics. We are moving towards a consensus that the role of central governments and intergovernmental …
One of the critical problems of contemporary global health is how to provide access to life-saving direct-acting antivirals (DAAs) to treat the hepatitis C virus (HCV). DAAs are recently launched drugs that have demonstrated cure rates exceeding 90%, which has revolutionized the fight against this epidemic. Given the promising results of such therapies, the World Health Organization launc…
| 2 / 2 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 4 / 4 | All Scholarships |
| Associated processes | |
CV Lattes
ORCID